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bjectives We evaluated transcatheter aortic valve implantation (TAVI) in high-risk patients with
icuspid aortic valve (BAV) stenosis.
ackground TAVI shows promise in the treatment of severe stenosis of triscupid aortic valves, espe-
ially in high-risk patients. However, BAV stenosis has been considered a contraindication to TAVI.
ethods Eleven patients (age 52 to 90 years) with symptomatic severe BAV stenosis underwent
AVI at 3 Canadian tertiary hospitals between May 2006 and April 2010. All patients were consid-
red high risk for surgical aortic valve replacement. Edwards-SAPIEN transcatheter heart valves (Ed-
ards Lifesciences, Inc., Irvine, California) were used. Transfemoral or transapical access was selected,
epending on the adequacy of femoral access.
esults Access was transfemoral in 7 patients and transapical in 4 patients. There were no intrapro-
edural complications. Signiﬁcant symptomatic and hemodynamic improvement was observed in 10
f 11 patients. Baseline aortic valve area of 0.65  0.17 cm2 and mean transaortic pressure gradient
f 41  22.4 mm Hg were improved to 1.45  0.3 cm2 and 13.4  5.7 mm Hg, respectively. Two
atients had moderate perivalvular leaks. At the 30-day follow-up there were 2 deaths due to multi-
ystem failure in 2 transapical patients. In 1 patient an undersized, suboptimally positioned, unstable
alve required late conversion to open surgery.
onclusions TAVI in selected high-risk patients with severe BAV stenosis can be successfully per-
ormed with acceptable clinical outcomes but will require further evaluation. (J Am Coll Cardiol
ntv 2010;3:1122–5) © 2010 by the American College of Cardiology Foundation
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1123icuspid aortic valves (BAV) occur in approximately 1% of
he population (1), making this the most common congen-
tal cardiac anomaly. Although silent until adulthood, ste-
osis and/or incompetence often develop in mid-life, re-
uiring aortic valve replacement. Transcatheter aortic valve
mplantation (TAVI) is an emerging alternative technique
hat has shown promise in the treatment of severe aortic
tenosis in patient populations at high risk with conven-
ional surgery (2). The presence of a BAV has been
onsidered an exclusion for TAVI. We describe our expe-
ience with TAVI in high-risk patients of severe aortic
tenosis due to BAV.
ethods
atients referred with severe symptomatic aortic stenosis due to
AV were assessed for TAVI in 3 Canadian tertiary hospitals.
ll patients were considered to be ineligible or high risk for
onventional aortic valve replacement surgery by a multidisci-
linary group of cardiologists and cardiac surgeons. Informed,
ritten consents were obtained. Patients with adequate femo-
al access underwent transfemoral TAVI; otherwise, transapi-
al access was used.
The details of the TAVI procedure have been described
lsewhere (3,4). General anesthesia, transesophageal echo-
ardiography (TEE), pre-implantation balloon aortic valvu-
oplasty, and rapid ventricular pacing to reduce cardiac
utput were routinely used (5). In transarterial procedures,
he Retroflex delivery system was used, followed by percu-
aneous or surgical closure of the femoral artery. In transapi-
al procedures, the Ascendra delivery system was used with
urgical closure of the left ventricular apex and thoracotomy.
Edwards-SAPIEN transcatheter heart valves (Edwards
ifesciences, Inc., Irvine, California) were used. Two sizes
ere available, with an external diameter of 23 or 26 mm.
n echocardiographic annulus diameter between 18 and
1 mm was considered suitable for the smaller valve and
etween 21 and 26 mm for the larger valve. Transthoracic
chocardiography was used for screening purposes, and
ntraprocedural TEE was used for final measurement of the
iameter of the aortic annulus.
esults
atients. TAVI was performed in 11 patients with stenotic
AV between May 2006 and March 2009 at St. Paul’s
ospital (n  8), Quebec Heart and Lung Institute (n  2),
nd Hamilton Health Sciences Centre (n 1). Mean age was
3.2 12.5 years (range 52 to 90 years); there were 6 men and
women. The Society of Thoracic Surgeons (STS) estimated
urgical mortality was 4.4  2.6%. Although STS scores do
ot reflect a high-risk population, many patients had comor-
idities that are not fully accounted for by the STS score,
ncluding end-stage liver failure (n  2) and frailty (n  4). wBaseline transthoracic echocardiography before the
AVI reported a mean aortic valve area of 0.65  0.17 cm2
nd mean gradient of 41.0  22.4 mm Hg. No patient had
ore than mild aortic incompetence. One patient had
evere mitral regurgitation. Ten of these patients had
ongenital bicuspid valves, whereas the other had a func-
ional bicuspid valve. Seven of them had severely calcified
alves, whereas the other 4 had moderate calcification. Left
entricular ejection fraction was 46.7  16.1%. The diam-
ters of the aortic root were approximately the upper limits
f normal; left ventricular outflow tract was 22.1  1.9 mm
transthoracic echocardiography), aortic annulus was 24.0
.3 mm (TEE), aortic root at the level of sinuses of Valsalva
as 39.4  5.8 mm (aortography), and ascending aorta was
8.3  4.6 mm (aortography).
rocedural outcome. Valves were successfully implanted in
ll 11 patients. Access was transfemoral in 7 patients and
ransapical in 4 patients. The 26-mm Edwards-SAPIEN
alve (Edwards Lifesciences, Inc.) was used in 10 patients,
hereas a 23-mm valve was used in 1 patient. Pre-
mplantation balloon valvuloplasty was done with a balloon
to 3 mm smaller in diameter
ompared with the aortic annular
ize. Full balloon expansion could
e achieved in all the cases. None
f the patients developed signifi-
ant aortic incompetence after
alloon valvuloplasty.
The position of the implanted
alve was optimal in 10 patients.
n these 10 patients, there was
ignificant hemodynamic im-
rovement with a reduction in
ean pressure gradient to 13.4  5.7 mm Hg and an
ncrease in mean valve area to 1.45  0.3 cm2. All valves
ppeared to open relatively symmetrically with a circular
ppearance on TEE (Fig. 1). No patient had significant
alvular aortic incompetence after valve implantation. Three
atients had moderate perivalvular leaks. In the single
atient with severe mitral regurgitation, this was reduced to
oderate and remained stable. Left ventricular ejection
raction rose from 46.7  16.1% to 56.0  16.3%.
In 1 transapical case the annulus was thought to be
uitable for a 26-mm valve on the basis of transthoracic
chocardiography. However, intraprocedural echocardiog-
aphy documented a 28-mm annulus. The valve was de-
loyed too ventricular with a native leaflet incompletely
overed by and extending over the valve frame. There was an
nitial modest improvement in valve area and gradient.
ollow-up. The 30-day survival was 82%. At a median
ollow-up of 208 days (interquartile range: 21.5 to 534.5
ays, longest follow-up: 1,172 days), 7 patients (all trans-
emoral access patients) remained alive. They also remained
Abbreviations
and Acronyms
BAV  bicuspid aortic
valve(s)
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiographyith minimal symptoms (New York Heart Association
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1124unctional class II dyspnea in all 7 patients, and Canadian
ardiovascular Society functional class II angina in 1
atient). Of the 4 transapical access patients, 2 died of
ultisystem failure on days 2 and 5. The transapical patient
ith a malpositioned prosthesis was documented to have
rogressive displacement of the prosthesis into the left
entricular outflow tract with recurrent stenosis and wors-
ning regurgitation. Late conversion to open surgery was
ollowed by death at 63 days. The last transapical patient
ied of a noncardiac cause at 208 days.
Follow-up transthoracic echocardiography (median
ollow-up of 387 days [interquartile range: 88 to 602 days,
ongest follow-up: 1,074 days]) showed well-functioning
alve prostheses in all living patients with a mean aortic
alve area of 1.4  0.35 cm2 and mean gradient of 13.9 
.7 mm Hg. No patient had significant valvular aortic
ncompetence, whereas 1 remained with a moderate peri-
alvular leak. The patient who had severe mitral regurgita-
ion before aortic valve implantation remained to have
oderate mitral regurgitation. Left ventricular ejection
raction improved from 49.4  15.6% (before aortic valve
Figure 1. Transesophageal Echocardiography
(A) Severely stenosed bicuspid aortic valve. (B) A bicuspid aortic valve after Ed
tricuspid aortic valve. (D) A tricuspid aortic valve after Edwards SAPIEN valve (
fully expanded and symmetrical.mplantation) to 62.6  9.5%. Tiscussion
AV is the most common congenital cardiac anomaly. It
as been suggested this condition might be responsible for
ore morbidity and mortality than all other congenital
ardiac malformations (6). It is heritable (7,8) and more
ommon in men (9,10), and the pathogenesis is unknown.
n a large clinicopathologic study of 542 patients with BAV,
5% had pure aortic stenosis, 13% had pure aortic insuffi-
iency, and 10% had combined aortic stenosis and insuffi-
iency (9).
BAV stenosis reportedly comprises 30% to 50% of all
dult patients undergoing aortic valve replacement surgery
or severe aortic stenosis (11,12). However, BAV have
enerally been considered to contraindicate TAVI, because
f the presumed risk of poor seating or paravalvular regur-
itation due to severe distortion of the native valve leaflets.
ecause BAV disease has generally been an exclusion
riterion in major trials of TAVI, there is little clinical
xperience available.
Little is known about the biomechanical requirements for
SAPIEN valve (Edwards Lifesciences, Inc.) implantation. (C) Severely stenosed
ds Lifesciences, Inc.) implantation. The balloon-expandable valves appearwards
EdwarAVI in the setting of BAV disease. In 1 intraoperative study,
a
i
b
s
c
d
m
s
t
r
i
o
c
v
a
P
t
p
l
p
t
s
d
r
b
w
a
h
C
S
b
o
R
P
b
R
1
1
1
1
1
1
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 1 , 2 0 1 0 Wijesinghe et al.
N O V E M B E R 2 0 1 0 : 1 1 2 2 – 5 Bicuspid Aortic Valve
1125n experimental transcatheter valve was temporarily implanted
n patients with both bicuspid and tricuspid aortic stenosis
efore conventional aortic valve replacement (13). Noncircular
tent expansion consistently occurred in the bicuspid valves
ompared with one-third of tricuspid valves. However, balloon
ilation of the native valve was not performed, and the
echanical characteristics of this particular self-expanding
tent used might not be comparable to clinically available
ranscatheter valves. In addition, self-expanding stents typically
ely on the unique properties of nitinol, which include an
ncrease in maximal radial force with the passage of time, initial
verexpansion, and core body temperature (14,15).
It is notable that valve expansion appeared relatively
ircular on TEE in all 11 cases. This suggests that a bicuspid
alve does not necessarily preclude symmetric expansion of
balloon-expandable valve with sufficient radial strength.
aravalvular regurgitation was trivial or mild in most pa-
ients, suggesting that bicuspid valves do not necessarily
reclude effective sealing. However, moderate paravalvular
eaks in 2 patients and the occurrence of late migration in 1
atient suggest that secure seating of the prosthesis within
he native annulus might be more difficult and accurate
izing might be more critical than with tricuspid valves.
The success of TAVI in bicuspid aortic stenosis might
epend on the selection of appropriate patients. Successful
esults could likely be achieved in patients with calcified
icuspid valves and predominant aortic stenosis. Patients
ith bulky leaflets, enlarged aortic root, dilated ascending
orta, and significant aortic incompetence might be at a
igher risk of failure to achieve successful results.
onclusions
elected high-risk patients with bicuspid aortic stenosis can
e successfully treated with TAVI with acceptable clinical
utcomes.
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